This Month in AJP  by unknown
The American Journal of Pathology, Vol. 184, No. 2, February 2014ajp.amjpathol.orgThis Month in AJP
CAR Selectively Enhances Drug Efﬁcacy in PAH
A major limitation in the treatment of pulmonary arterial
hypertension (PAH) is the lack of pulmonary vascular
selectivity. Toba et al (Am J Pathol 2014, 184:369e375)
tested the effect of co-administration of CARSKNKDC
(CAR), which speciﬁcally targets PAH vasculature, on three
vasodilators in hypoxia/normoxia-exposed PAH rats. Intra-
venously co-administered CAR enhanced pulmonary but not
systemic effects of the vasodilators fasudil and imatinib in
PAH rats. CAR increased lung tissue imatinib concentration
in isolated PAH lungs without increasing pulmonary vascular
permeability. Sublingual CAR was also effective in selec-
tively enhancing the pulmonary vasodilation by imatinib and
sildenaﬁl. These results suggest a new paradigm for target
tissue-speciﬁc pharmacological intervention in PAH.
Micro-CT Uncovers Tumor Micromorphology and
Vascularization
Using four tumor models characterized by different degrees of
aggressiveness and angiogenesis, Ehling et al (Am J Pathol
2014, 184:431e441) tested the ability of X-ray micro-
computed tomography (mCT) to yield accurate relative blood
volume (rBV) quantiﬁcation. rBV values obtained via in vivo
mCT ranged from 2.6% to 6.0%, similar to IHC values. Ultrae
high-resolution ex vivo mCT enabled visualization of blood
vessels as small as 3.4mmand vessel branches up to the seventh
order.Vessel size and vessel branching correlated verywellwith
tumor aggressiveness and angiogenesis. Thus, combining
highly accurate functional with highly detailed anatomical mCT
represents a useful tool for facilitating high-throughput quanti-
tative and translational angiogenesis research.
Diuretics Prevent Thiazolidinedione-Induced
Cardiac Hypertrophy
Thiazolidinedione (TZD)-induced cardiac hypertrophy (CH)
has been attributed to an increase in plasma volume or a
change in cardiac nutrient preference. To test the hypothesis
that TZD-induced CH is directly mediated through volume
expansion, Chang et al (Am J Pathol 2014, 184:442e453)
released TZD-induced volume overload by feeding mice di-
uretics and examined PPARg dependence by using PPARgCopyright ª 2014 American Society for Investigative Pathology.
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for ligand binding (PpargP465L/þ). Rosiglitazone-induced
CH in mice was mediated through PPARg activation and
required intact ligand binding. Diuretics attenuated
rosiglitazone-induced CH, hypertrophic gene reprogram-
ming, cardiomyocyte apoptosis, hypertrophyrelated signal
activation, and left ventricular dysfunction. Such a successful
cotreatment strategy could be easily adopted in a clinic.
a7 nAChR Agonist Enhances Cognition
Enhancing cholinergic signaling with acetylcholinesterase in-
hibitors remains the primary strategy for improving cognition in
Alzheimer disease (AD), though the beneﬁts are typically short-
lived. Medeiros et al (Am J Pathol 2014, 184:520e529)
examined the effect of long-term treatment with a selective a7
nicotinic acetylcholine receptor (nAChR) agonist (A-582941)
in aged 3xTg-ADmicewith robustAD-like pathology.Overall,
pathologicalﬁndings (b-amyloid deposits, tauphosphorylation,
and neuroinﬂammation) were unchanged. However, cognition
was completely restored in aged 3xTg-AD mice to the level of
that in age-matched nontransgenic mice and was accompanied
by activation of transcriptional factors c-Fos and CREB, up-
regulation in BDNF levels, and phosphorylation of the TrkB
receptor. Activating a7 nAChR may be a promising treatment
for cognitive impairment in AD.
Cervical Cancer Recurrence after Raloxifene
Treatment
The selective estrogen receptor modulator (SERM) raloxifene
promotesregressionofhigh-gradedysplasiaandcancerarisingin
the cervix ofK14E6/E7 transgenicmice treated chronicallywith
estrogen. Spurgeon et al (Am J Pathol 2014, 184:530e540)
evaluated the recurrence of cervical cancer following raloxifene
therapy in these mice. Neoplastic disease recurred following
cessation of raloxifene treatment regardless of exogenous estro-
gen, though it did increase the severity of the recurrent neoplastic
disease. All recurrent cancers retained an active estrogen/ERa
signaling pathway and were responsive to retreatment with ral-
oxifene, and maintaining mice on raloxifene prevented high
recurrence rates. This study supports the premise that SERMs
may be effective in treating HPV-associated human cervical
cancers, but their effectivenessmay require long-term treatment.
